The prescribing pathway under scrutiny
The legal and regulatory debate surrounding these medicines has largely centred on safety, side effects and potential adverse outcomes. These issues are important and will continue to attract scrutiny as demand increases.
However, as private prescribing becomes increasingly common, it may be that the most significant liability risks lie not in the medicines themselves, but in the systems and processes surrounding their prescription.
What happens when demand for a medicine grows faster than the systems designed to prescribe it safely?
Private prescribing now dominates access to weight-loss medicines in the UK and Ireland. Patients can access treatment through private clinics, pharmacies, online providers and telehealth services, often with a speed and convenience that would have been unthinkable only a few years ago.
That wider access is not inherently problematic. Indeed, it has enabled many patients to obtain treatment that may previously have been difficult to access. However, it also shifts greater attention to the prescribing pathway itself.
Future claims are likely to focus as much on the prescribing process as on the outcome, with the key question being whether the decision to prescribe can be shown to have been clinically appropriate and supported by appropriate assessment, consent and documentation.
Questions such as the following are likely to be familiar to anyone involved in healthcare litigation:
- Was the patient an appropriate candidate for the drug?
- Were contraindications identified?
- Was informed consent properly obtained?
- Was adequate follow-up arranged?
- Can any of those discussions now be evidenced?
The challenge is that these questions are increasingly being asked in an environment where prescribing may be taking place remotely, at scale and often through commercial models designed around accessibility and convenience.
Consent, monitoring and continuity of care
Consent processes may come under increasing scrutiny as prescribing volumes continue to grow. Patients frequently arrive having consumed large amounts of information through social media, online forums, news coverage and provider websites. While that increased awareness can be beneficial, it may also create unrealistic expectations regarding the likely pace of weight loss, long-term outcomes and potential risks.
In any future claim, the issue may not be whether information about weight-loss medicines was generally accessible to the patient. More likely, scrutiny will focus on whether material risks, benefits, alternatives, expected outcomes and treatment limitations were explained in the context of that patient's individual circumstances, and whether those discussions were properly documented.
Follow-up and continuity of care are also likely to come under scrutiny. Many patients engage with multiple healthcare providers during their treatment journey. Initial prescribing may occur through an online provider, monitoring may be undertaken elsewhere, and subsequent medical care may involve the patient's GP or secondary care services.
Where concerns arise or adverse events develop, responsibility for monitoring, escalation and review may not always be straightforward. In a fragmented treatment pathway, providers will need to demonstrate who was responsible for ongoing monitoring, what advice was communicated to the patient and other healthcare professionals, and how those responsibilities were documented.
The consumerisation of prescription medicines
The wider context is also changing. Weight-loss medicines increasingly sit at the intersection of healthcare, aesthetics, wellness and retail marketing.
Patients are exposed not only to clinical information, but also to influencer content, celebrity endorsements, online testimonials and highly targeted digital advertising, often long before they encounter a clinician.
This consumerisation of prescription medicines creates challenges that are relatively unfamiliar in more traditional prescribing environments. Patients may approach consultations with strong expectations regarding outcomes, preferred treatment choices and perceptions of risk that have been shaped before any clinical assessment takes place.
In that environment, the distinction between a consumer seeking a product and a patient seeking medical treatment can become blurred. From a liability perspective, this places even greater importance on ensuring that clinical decision-making remains independent, patient-specific and capable of withstanding retrospective scrutiny.
As demand has surged, weight-loss services have become increasingly visible online. Providers must navigate the boundary between promoting a legitimate clinical service and creating unrealistic expectations about treatment.
Advertising, onboarding materials, website content and patient-facing communications are not simply marketing tools. They play an important role in patient expectations, communicating risks and supporting informed decision-making. Where allegations later arise that benefits were overstated or risks understated, those materials may also form part of the evidential picture. Governance, therefore, extends well beyond the consultation room and into every stage of the patient journey.
Regulatory fragmentation and accountability
The regulatory landscape adds a further layer of complexity.
Unlike many areas of healthcare, various aspects of the weight-loss market fall within the oversight of multiple regulators and professional bodies, including those concerned with medicines regulation, advertising standards, pharmacy services, healthcare delivery and professional conduct.
Each regulator has a distinct role, resulting in a fragmented oversight framework in which responsibility for different aspects of the patient journey may be distributed across several organisations.
For providers delivering high-volume prescribing services, compliance extends beyond clinical assessment alone. It also requires careful consideration of patient verification processes, marketing activity, consent procedures, record keeping and governance arrangements.
Where adverse outcomes occur, providers may face regulatory investigations, professional conduct concerns and civil claims arising from the same underlying events.
Emerging risks beyond approved products
The extraordinary demand for obesity treatments is already creating risks that sit outside traditional prescribing and regulatory structures.
One of the more striking developments has been the emergence of both counterfeit versions of licensed weight-loss medicines and illicit versions of investigational products before regulatory approval. In March 2026, the Health Products Regulatory Authority (HPRA) reported a substantial increase in the seizure of fake and illegal weight-loss medicines in Ireland. The regulator identified a sharp rise in products marketed as containing semaglutide or tirzepatide, including so-called "GLP-1 drops" and microneedle patches. Testing found that some products did not contain the active ingredients claimed on their packaging, highlighting the difficulty consumers face in verifying the authenticity or contents of medicines purchased outside legitimate supply channels.
More recently, in September 2026, the BBC reported concerns regarding the circulation of purported versions of Retatrutide, Eli Lilly's experimental obesity treatment, despite the medicine not yet having received approval from any medicines regulator. The report highlighted concerns that counterfeit versions of a medicine still undergoing late-stage clinical trials had already become widely available.
Whether such products contain the substances they purport to contain is often impossible for purchasers to verify. More importantly, they fall outside the safeguards, clinical oversight and pharmacovigilance systems that accompany legitimate prescribing. The HPRA has specifically warned that medicines obtained through unauthorised channels may be counterfeit, mislabelled, or contain harmful or ineffective ingredients, creating significant and avoidable risks to patient safety.
Their emergence demonstrates the extent to which commercial demand can outpace both regulation and supply. As new therapies move through the development pipeline, providers, regulators and insurers may increasingly find themselves navigating risks that arise not only from approved prescribing practices, but also from a growing parallel market in falsified, unregulated and unlicensed products.
Governance as the first line of defence
While the claims landscape continues to evolve, familiar healthcare litigation themes are already emerging: inappropriate prescribing, inadequate screening, deficient consent, poor follow-up and incomplete records.
In many cases, the central issue may not be the outcome itself. Recognised complications can occur despite appropriate care. The focus is likely to be on whether appropriate clinical judgment was exercised throughout the patient journey and supported by adequate records.
None of this distracts from the significant benefits these medicines can offer. The solution is not more restrictive prescribing. It is robust governance, clear clinical accountability and well-documented decision making. Ensuring that governance evolves as quickly as the market itself will be one of the sector's key legal and regulatory challenges.
For healthcare providers, the challenge is ensuring that clinical standards keep pace with increasing demand and increasingly consumer-focused delivery models. For insurers and indemnifiers, it is understanding how emerging risks may develop across a treatment pathway that extends well beyond the prescription itself.
When claims arrive, the central question may not be whether a prescription was written, but whether the pathway leading to that prescription was safe, reasonable and defensible.
Authors: Anna Haines-Smyth, Meslissa McParland and Philippa Varcoe
